Kaleebu, Pontiano; Levin, Jonathan; Nanvubya, Annet; Kibengo, Freddie; Jaoko, Walter; Pala, Pietro; Perreau, Matthieu; Namuniina, Annamarie; Kitandwe, Paul; Tapia, Gonzalo; +20 more... Serwanga, Jennifer; Yates, Nicole; Fast, Pat; Mayer, Bryan; Montefiori, David; Tomaras, Georgia; Robb, Merlin; Lee, Carter; Wagner, Ralf; Sanders, Edward; Kilembe, William; Kiwanuka, Noah; Gilmour, Jill; Kuipers, Hester; Vooij, Dani; Chinyenze, Kundai; Priddy, Frances; Ding, Song; Hanke, Tom; Pantaleo, Giuseppe; (2017) THE RESULTS OF THE EV06 DNA-PROTEIN COMBINATION TRIAL AND PLANS FOR GREAT, AN EDCTP2-FUNDED CONSERVED-MOSAIC EPITOPE HIV VACCINE TRIAL. BMJ Global Health, 2 (Suppl). A16.2-A16-. DOI: https://doi.org/10.1136/bmjgh-2016-000260.39

Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4651028/

DOI: https://doi.org/10.1136/bmjgh-2016-000260.39

Usage Guidelines:

Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Background These two trials under Europe-Africa collaborations aim at addressing two factors relevant for Africa i.e helminth infections and HIV-1 diversity. EV06 used a novel combination of DNA expressing clade C Env, Gag and Pol-nef co-administered with AIDSVAX® B/E Env protein to study the effect of S. mansoni on vaccine responses. GREAT is a recently awarded trial using a 2nd generation improved conserved tHIVConsvX T-cell vaccine candidate combined with bivalent mosaic design to increase breadth and protective epitopes.